Get started
Author

Fabiola Valvert

Observed names: F Valvert, F. Valvert, Fabiola Valvert Gamboa
ORCID: 0000-0003-0687-2419
Observed ORCID: 0000-0003-0687-2419
OpenAlex ID: A5069417815
Lymphotropic Viruses EBV, KSHV and HTLV in Latin America: Epidemiology and Associated Malignancies. A Literature-Based Study by the RIAL-CYTED
2020 · Paola Chabay, Daniela Lens, et al. · Cancers · 35
PDF
Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos
2021 · Luis Malpica, Daniel J. Enriquez, et al. · JCO Global Oncology · 33
PDF
Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma
2022 · Bethany L. Mundy-Bosse, Christoph Weigel, et al. · Blood Cancer Discovery · 30
PDF
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study
2025 · Luis Malpica, Henry Idrobo, et al. · The Lancet Haematology · 24
Low-cost transcriptional diagnostic to accurately categorize lymphomas in low- and middle-income countries
2021 · Fabiola Valvert, Oscar Silva, et al. · Blood Advances · 22
PDF
Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses
2024 · Edward L. Briercheck, Shashidhar Ravishankar, et al. · Blood Advances · 16
PDF
LymphoML: An interpretable artificial intelligence-based method identifies morphologic features that correlate with lymphoma subtype
2023 · Vivek Shankar, Xiaoli Yang, et al. · medRxiv · 15
PDF
Prevalence and survival outcomes of adult T-cell leukemia/lymphoma in Latin America: A multicenter cohort study and recommendations to improve diagnosis and outcomes
2025 · Bryan Valcarcel, Henry Idrobo, et al. · Cancer Epidemiology · 9
Epidemiology, Clinical Features and Outcomes of Peripheral T-Cell Lymphoma in Latin America
2023 · Thais Fischer, Henry Idrobo, et al. · Blood · 5
PDF
Consenso del Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL) para el manejo del Linfoma en estado de Pandemia SARS CoV-2 / COVID 19
2020 · Juan Alejandro Ospina Idárraga, Humberto Martinez-Cordero, et al. · Revista Colombiana de Cancerología · 5
PDF
A Novel Prognostic Index for Patients with EBV-DLBCL NOS: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
2021 · Brady E Beltran, Denisse Castro, et al. · Blood · 4
Clinicopathological Features and Outcomes of EBV Positive and Negative DLBCL: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
2021 · Denisse Castro, Brady E Beltran, et al. · Blood · 3
Epidemiology, Clinical Features, and Outcome of HTLV-1-Related Adult T-Cell Leukemia/Lymphoma in Latin America: A Study from the Latin American Group of Lymphoproliferative Disorders (GELL)
2020 · Luis E Malpica Castillo, Daniel J Enriquez, et al. · Blood · 3
Comparing Hodgkin and Non-Hodgkin Lymphoma Mortality Between Latin America and the United States From 2008 to 2019: The Need of Regional-Based Lymphoma Registries
2025 · Bryan Valcarcel, German Stemmelin, et al. · JCO Global Oncology · 2
Uncovering the Epidemiology, Therapy Patterns and Outcomes of MALT Lymphoma in Latin America: A Multinational Retrospective Cohort Study
2024 · Monica Labrano Elias, Seisha Von Glasenapp, et al. · Blood · 2
PDF
Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
2024 · Juan Esteban Garcia-Robledo, Henry Quintero, et al. · Blood · 2
Validating the Systemic Inmmune-Inflamation Index (SII) As a Prognostic Biomarker of Overall Survival in Diffuse Large B-Cell Lymphoma: A Retrospective Analyses By the Gruppo De Estudio Latinoamericano De Linfoproliferativos (GELL)
2023 · Luis Mario Villela Martinez, Brady E Beltran, et al. · Blood · 2
PDF
Validating the Halp Score (Hemoglobin,Albumin, Lymphocytes, and Platelets) and the Neutrophil/Lymphocyte Ratio ( NLR ) As Prognostic Factors for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. Retrospective Analysis By the Grupo De Estudio De Latino America De Linfoproliferativos (GELL)
2023 · Luis Mario Villela Martinez, Brady E Beltran, et al. · Blood · 2
Oncology Institute of Guatemala: Experience With NK/T-Cell Lymphomas
2016 · Fabiola Valvert, Diana Flores · Journal of Global Oncology · 2
Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium
2025 · Mark Sorial, Kenechukwu Aniagboso, et al. · Blood · 1
Comparative effectiveness of R-minichop versus R-CHOP in older patients with diffuse large B-cell lymphoma: A propensity score-matched analysis from a real-world grupo de estudio latinoamericano de linfoproliferativos (GELL) cohort
2025 · Rafael Pichardo-Rodriguez, Luis Mario Villela Martinez, et al. · Blood · 1
PDF
Selection of CUT-Off Points for Prognostic Biomarkers in Lymphoma Using Restricted Cubic Splines: Experience of the Grupo De Estudio De Linfoproliferativos De Latinoamérica (GELL) in a Cohort of Diffuse Large B-Cell Lymphoma Patients
2024 · Rafael Martin De Jesus Pichardo Rodriguez, Brady Beltran, et al. · Blood · 1
PDF
Dose-Response Relationship between Inflammatory Biomarkers and Overall Survival Using Restricted Cubic Splines: Experience of the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL) in a Cohort of Diffuse Large B-Cell Lymphoma
2024 · Rafael Martin De Jesus Pichardo Rodriguez, Brady Beltran, et al. · Blood · 1
Epidemiology of Lymphomas in Latin America
2024 · Brady Beltran, Maria Torres, et al. · JCO Global Oncology · 1
Primary CNS Lymphoma in Latin America: A Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL) Survey in 80 Cancer Centers in Latin America
2023 · Guilherme Fleury Perini, Henry Idrobo, et al. · Blood · 1
PDF
Works count: 64
Citation count: 226
H-index: 8
I10-index: 7
Year
Topic
Type